The Protein Myth: Our Obsession With Protein and How It Is Killing US

Houston Methodist

G. Davis

Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Physicians Committee for Responsible Medicine

T. J. Key

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Medications for Weight Loss: The New Satiety Hormones

Scripps Health

K. Fujioka

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

Weightloss in Menopause

Susan Brian

Do Triglycerides Cause Heart Disease?

National Lipid Association

I. Goldberg

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

GLP-1 Agonists and GI: All We Need to Know

UT Health San Antonio School of Medicine

P. Jirapinyo

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

MAFLD: What Is It?

Houston Methodist

D. Victor

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Heart Failure in Women: 2025 Update

Scripps Health

M. Kittleson

Tirzepatide Updates

Diana Isaacs

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

The Deadly Paradox: Current Practice, Driven by Guidelines, Is Not A…

Michael Makover